Case Study
Commercial Consulting – Five Senior Functions, No Permanent Headcount (Clinical-Stage Oncology)
12 Senior Specialists Engaged | 7 Peak Concurrent | 18 Months | 5 Functions Covered
The Challenge:
A clinical-stage biopharmaceutical company with a late-stage oncology program was preparing for a potential commercial launch. The organization had no internal commercialization or late-stage regulatory infrastructure, and needed Regulatory Submissions, Market Access, HEOR, RWE, Epidemiology, and Post-Marketing Safety operating in parallel rather than in sequence.
Hiring permanently into five functions would have added significant fixed overhead ahead of product revenue.
The Approach:
Over 18 months BioPoint placed and supported 12 senior specialists across five functions, adding and releasing resources as each workstream required. The team peaked at seven concurrent.
Specialists worked inside the client’s organization and reported to client leadership. BioPoint sourced them, managed the commercial relationship, and adjusted the mix as priorities shifted.
Market Access & Strategy
An interim Market Access Lead developed the US access roadmap, authored the AMCP Value Dossier, and supported pre-approval payer engagement.
HEOR & RWE
HEOR consultants built cost-effectiveness and budget impact models to show therapeutic value and cost offset for commercial health plans.
Epidemiology & RWD
Epidemiologists and RWD analysts ran observational analyses to define disease burden and real-world standard-of-care benchmarks, working within the client’s existing data access.
Regulatory Strategy & Submissions
A Senior Regulatory Affairs Lead managed eCTD preparation, authored core submission modules, and supported agency interactions during the review.
Drug Safety & Pharmacovigilance
Senior pharmacovigilance experts helped build post-marketing safety infrastructure and aggregate reporting systems, and prepared the framework for anticipated post-approval commitments.
The Result:
The client’s launch-readiness framework was in place ahead of their internal timeline.
Pre-approval payer engagement was underway and safety readiness was in place ahead of the review milestone. Because the team was flexible rather than permanent, the client avoided fixed headcount it would have carried through an uncertain regulatory outcome. Each function scaled up or down as priorities shifted.